Price history
¥200Latest-38.3%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 20
PER
31.95How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
0.88How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
2.8%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥2.3bnShare price × number of shares. The value of the entire company.Equity ratio
46.5%The proportion of assets funded by money that does not have to be repaid.Operating margin
5.7%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
3.3%The average annual growth in sales over the past three years.What to watch next
Improvement in utilization and costs from plant upgrades and equipment renewal in the water sales business, leading to higher productivity and quality
Over the next 12 months and beyond (to be confirmed through capex progress and the next disclosure)Impact HighLikelihood Medium
Progress in the market launch and scaling of purified-water dispensers in the water sales business (sales volume and expansion of distributors and sales agents)
During the fiscal year from 2026 onwardImpact MediumLikelihood Medium
Contribution from expanding the EC business and private-label planning and development in household medicines (rising share of private-label sales)
To be confirmed quantitatively from the next annual or interim resultsImpact MediumLikelihood Medium
Sustainability of new-customer acquisition through new locations, including satellite offices, as part of the sales-channel expansion initiatives
From the second half of 2026Impact MediumLikelihood Low
Cost impact of higher raw-material and energy prices and yen depreciation, and the success or failure of passing these costs on through pricing
Quarterly (an ongoing issue)Impact HighLikelihood Medium
What to watch next
Who owns itTop holders total 31.7%
Listed holders 31.7%Everyone else 68.3%
株式会社マサユキコーポレーション14.94%
Yamada Masayuki (山田 正行)3.07%
Saotome Shuji (早乙女 修司)2.66%
知多信用金庫1.83%
J.P. Morgan Securities Co., Ltd.1.82%
Custody Bank of Japan, Ltd. (Trust Account).1.81%
中京医薬品従業員持株会1.48%
杉浦 直幸1.41%
2 other listed holders2.70%
| Holder | Ownership (%) |
|---|---|
| 株式会社マサユキコーポレーション | 14.94 |
| Yamada Masayuki (山田 正行) | 3.07 |
| Saotome Shuji (早乙女 修司) | 2.66 |
| 知多信用金庫 | 1.83 |
| J.P. Morgan Securities Co., Ltd. | 1.82 |
| Custody Bank of Japan, Ltd. (Trust Account). | 1.81 |
| 中京医薬品従業員持株会 | 1.48 |
| 杉浦 直幸 | 1.41 |
| 2 other listed holders | 2.70 |
This company's documents
Filings
Timely disclosures
- 2026-08-05Earnings Report for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated)
- 2026-07-17Notice of Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation for Directors
- 2026-06-25Notice Regarding the Disposal of Treasury Shares as Restricted Stock Compensation for Directors
- 2026-06-12Notice of Personnel Changes
- 2026-06-02Notice of Convocation of the 2026 Annual General Meeting of Shareholders
- 2026-05-13Notice Regarding Changes in Officers
- 2026-05-13Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Non-consolidated)